【瞩目】康恩贝拿下13亿大品种

米内网08-12

精彩内容日前，康恩贝公告称，其全资子公司金华康恩贝申报的4类仿制药恩替卡韦片（0.5mg、1mg）获批生产并视同过评。恩替卡韦片属于鸟嘌呤核苷类似物，2023年在中国三大终端六大市场（统计范围详见本文末）的销售额超过13亿元。恩替卡韦片是一种鸟嘌呤核苷类似物，对乙型肝炎病毒(HBV)多聚酶具有抑制作用，适用于病毒复制活跃、血清丙氨酸氨基转氨酶(ALT)持续升高或肝脏组织学显示有活动性病变的慢性成人...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2458671594?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2024-08-12 16:37","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2458671594","market":"sh","top_or_hot":-1,"title":"【瞩目】康恩贝拿下13亿大品种","media":"米内网","content":"<div>\n<p>精彩内容日前，康恩贝公告称，其全资子公司金华康恩贝申报的4类仿制药恩替卡韦片（0.5mg、1mg）获批生产并视同过评。恩替卡韦片属于鸟嘌呤核苷类似物，2023年在中国三大终端六大市场（统计范围详见本文末）的销售额超过13亿元。恩替卡韦片是一种鸟嘌呤核苷类似物，对乙型肝炎病毒(HBV)多聚酶具有抑制作用，适用于病毒复制活跃、血清丙氨酸氨基转氨酶(ALT)持续升高或肝脏组织学显示有活动性病变的慢性成人...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202408121652039f23eeb0&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>【瞩目】康恩贝拿下13亿大品种</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n【瞩目】康恩贝拿下13亿大品种\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-08-12 16:37 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202408121652039f23eeb0&s=b><strong>米内网</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>精彩内容日前，康恩贝公告称，其全资子公司金华康恩贝申报的4类仿制药恩替卡韦片（0.5mg、1mg）获批生产并视同过评。恩替卡韦片属于鸟嘌呤核苷类似物，2023年在中国三大终端六大市场（统计范围详见本文末）的销售额超过13亿元。恩替卡韦片是一种鸟嘌呤核苷类似物，对乙型肝炎病毒(HBV)多聚酶具有抑制作用，适用于病毒复制活跃、血清丙氨酸氨基转氨酶(ALT)持续升高或肝脏组织学显示有活动性病变的慢性成人...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202408121652039f23eeb0&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0239","symbol_name":"医药制造","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202408121652039f23eeb0&s=b","article_id":"2458671594","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202408121652039f23eeb0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2458671594","pubTimestamp":1723451859,"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"精彩内容日前，康恩贝公告称，其全资子公司金华康恩贝申报的4类仿制药恩替卡韦片获批生产并视同过评。恩替卡韦片为国家医保乙类品种，2023年在中国三大终端六大市场的销售额超过13亿元。今年以来，康恩贝有恩替卡韦片、吸入用乙酰半胱氨酸溶液、盐酸托莫西汀口服溶液、盐酸文拉法辛缓释胶囊、他达拉非片等5个品种获批生产并视同过评。康恩贝已过评品种来源：米内网一致性评价进度数据库","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"600572":"康恩贝","BK0239":"医药制造","BK0012":"证金概念","BK0097":"医药电商","BK0028":"国家队","BK0188":"融资融券","BK0060":"抗癌"},"translate_title":"[Attention] Conba won 1.3 billion large varieties","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"600572":1},"content_text":"精彩内容日前，康恩贝公告称，其全资子公司金华康恩贝申报的4类仿制药恩替卡韦片（0.5mg、1mg）获批生产并视同过评。恩替卡韦片属于鸟嘌呤核苷类似物，2023年在中国三大终端六大市场（统计范围详见本文末）的销售额超过13亿元。恩替卡韦片是一种鸟嘌呤核苷类似物，对乙型肝炎病毒(HBV)多聚酶具有抑制作用，适用于病毒复制活跃、血清丙氨酸氨基转氨酶(ALT)持续升高或肝脏组织学显示有活动性病变的慢性成人乙型肝炎的治疗。恩替卡韦片为国家医保乙类品种，2023年在中国三大终端六大市场的销售额超过13亿元。受国采执行影响，该产品近年来在院内市场（公立医院+公立基层医疗）的销售额持续下滑。米内网数据显示，目前国内已有29家企业的恩替卡韦片过评或视同过评，包括广东东阳光药业、浙江华海药业、齐鲁制药、石药欧意药业、福建广生堂药业、宜昌人福药业、重庆药友制药、康恩贝等。今年以来，康恩贝有恩替卡韦片、吸入用乙酰半胱氨酸溶液、盐酸托莫西汀口服溶液、盐酸文拉法辛缓释胶囊、他达拉非片等5个品种获批生产并视同过评。目前公司有27个品种过评或视同过评，集中在消化系统及代谢药（7个）、全身用抗感染药物（5个）等治疗领域，其中泮托拉唑钠肠溶片、复方磺胺甲恶唑片为首家过评。康恩贝已过评品种来源：米内网一致性评价进度数据库","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.28.1","shortVersion":"4.28.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2458671594"}